Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals — Investor Presentation (November 2025)

21 slides from Centessa Pharmaceuticals's investor presentation, Nov 5, 2025

  1. Slide 1: November 2025 Corporate Overview

    November 2025 Corporate Overview

  2. Slide 2: Disclaimer and forward-looking statements

    2 2 This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as

  3. Slide 3: Centessa investment highlights and mission

    Centessa reported $349.0 million in cash, cash equivalents and investments as of September 30, 2025. Cash runway estimated into mid-2027. Potential best -in-class / first-in-class orexin receptor 2 (OX2R) agonist franchise Robust series of clinical milestones anticipated across OX2R agonist pipeline

  4. Slide 4: Orexin anticipated milestones 2025 and 2026

    ORX750 Phase 2a data in patients with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) in 2025 Registrational program planned for Q1 2026 ORX142 Phase 1 data in acutely sleep -deprived healthy volunteers in 2025 Patient studies planned for Q1 2026 ORX489 Advancing in

  5. Slide 5: Orexin agonists could transform standard of care

    Orexin agonists have the potential to transform the standard of care for individuals with sleep-wake, neurological, neurodegenerative and neuropsychiatric disorders 5

  6. Slide 6: Targeting a key signaling neuropeptide implicated in numerous therapeutic areas

    Wakefulness Cognition Orexin Dopamine (Ventral tegmental area) Serotonin (Raphe nuclei) Acetylcholine (Basal forebrain) Sources: Pizza, F et al., J Sleep Res 2022;31(4):e13665; Toor, B et al., Front Neurol Neurosci 2021;45:38 ; Ten-Blanco, M et al., Front Neuroendo 2023;69:101066; and, Yamamoto, H e

  7. Slide 7: Potential best-in-class / first-in-class OX2R agonist therapeutics

    ORX750 for the treatment of NT1, NT2 and IH ORX142 for the treatment ofneurological and neurodegenerative disorders Earlier stage OX2R agonists and therapeutics for additional potential indications ORX489 for the treatment ofneuropsychiatric disorders Molecule hOX2R EC50 (nM) Selectivity vs. hOX1R N

  8. Slide 8: Broad and rapidly advancing OX2R agonist pipeline

    ASSET DISEASE/CONDITION MECHANISM PRE -CLINICAL PHASE 1 PHASE 2 ORX750 Narcolepsy Type 1 (NT1) OXR2 Agonist ORX750 Narcolepsy Type 2 (NT2) OXR2 Agonist ORX750 Idiopathic Hypersomnia (IH) OXR2 Agonist ORX142 Neurological & Neurodegenerative Disorders OXR2 Agonist ORX489 Neuropsychiatric Disorders OXR

  9. Slide 9: Pipeline of highly potent, selective OX2R agonists enabled by proprietary structural biology

    Candidate Selection Criteria for a Best -in-Class Profile • Highly potent and highly selective • Optimal predicted PK profile • Low predicted human doses • Fast onset of action OX2R agonist Orexin -A: Highly Validated Pathway Proprietary Structure Based Drug Design Medicinal Chemistry SAR * *SAR is

  10. Slide 10: ORX750: potential to redefine the standard of care

    Expect to initiate registrational studies in Q1 2026 High unmet medical need in NT1, NT2 and IH ORX750 Highly potent, selective OX2R agonist Significant commercial opportunity as potential treatment for all three indications Phase 2a data from initial low dose cohorts demonstrate potential best -in-

  11. Slide 11: ORX750 Phase 2a study design and endpoints

    https://clinicaltrials.gov/study/NCT06752668 MWT and ESS are established registrational endpoints for EDS in sleep-wake disorders and weekly cataplexy rate is an established registration endpoint for cataplexy in NT1. *Measured by Narcolepsy Severity Scale (NSS) and Idiopathic Hypersomnia Severity S

  12. Slide 12: ORX750 safety and tolerability profile

    12 ORX750 has been observed to be generally well -tolerated at all doses tested across each indication with all treatment-emergent adverse events (TEAEs) being transient and mild to moderate in severity. 55 participants with NT1, NT2 and IH who have been dosed with ORX750 in the 2 -week crossover do

  13. Slide 13: ORX750 NT1 efficacy results

    Generally favorable safety and tolerability profile Clinically meaningful improvements across multiple efficacy measures Dose escalation across ongoing and future cohorts within a 4-week parallel design 1 MWT, Maintenance of Wakefulness Test; MSL, Mean Sleep Latency; ESS, Epworth Sleepiness Scale; P

  14. Slide 14: ORX750 NT2 and IH efficacy results

    Statistically significant and clinically meaningful improvements from baseline on multiple efficacy measures , including MSL on MWT with 2 mg dose | p-value =0.0213, n=17 NT2 IH MWT, Maintenance of Wakefulness Test; MSL, Mean Sleep Latency; ESS, Epworth Sleepiness Scale; PBO, Placebo; SE, Standard E

  15. Slide 15: ORX750 basket study design

    Innovative design with potential to enable well -powered and efficient data generation Optimal number of patients to allow efficient recruitment Potential for optimized dose selection Note: Study design for illustrative purposes only. Dosing started at 1.0 mg in NT1 and 2.0 mg in NT2 and IH once - d

  16. Slide 16: NT1, NT2, and IH represent large addressable patient populations

    EDS is excessive daytime sleepiness. Source of prevalent patient estimates: Acquavella et al., J Clin Sleep Med 2020; Saad et al., Sleep 2023; and Centessa market research. Source of diagnosed and treated patient estimates: Acquavella et al., J Clin Sleep Med 2020; Saad et al., Sleep 2023; and Ohayo

  17. Slide 17: Large market opportunity and efficient go to market

    Source: 1. Acquavella et al., J Clin Sleep Med 2020; Saad et al., Sleep 2023; and Centessa Market Research; 2. Prescribing information for current standard of care therapies; 3. FDA, “The Voice of the Patient: Narcolepsy” 2014; 4. Maski et al., J Clin sleep Med 2017; 5. American Association of Sleep

  18. Slide 18: ORX142 Phase 1 data in healthy volunteers

    ORX142 Rapid onset of action and differentiated pharmacokinetics >13,000 -fold selectivity vs. hOX1R ; EC50 0.069 nM for hOX2R Planned for the treatment of neurological and neurodegenerative disorders ORX142 18 Generally well -tolerated at all doses tested with all AEs being self -limited and either

  19. Slide 19: Building a class-leading franchise

    ORX750 Registrational program planned for Q1 2026 ORX142 Patient studies planned for Q1 2026 ORX489 Advancing in IND -enabling studies; Clinical studies planned for Q1 2026* 19*Subject to IND clearance Building a class -leading franchiseOREXIN

  20. Slide 20: Centessa cash position and mission

    Centessa reported $349.0 million in cash, cash equivalents and investments as of September 30, 2025. Cash runway estimated into mid-2027. Potential best -in-class / first-in-class orexin receptor 2 (OX2R) agonist franchise Robust series of clinical milestones anticipated across OX2R agonist pipeline

  21. Slide 21: Centessa Pharmaceuticals

    >< CENTESSA PHARMACEUTICALS

Centessa Pharmaceuticals — Investor Presentation (November 2025) on 6ix